Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (481-490 of 759) with videos related to

Pageof 76
Sort By:
Blood Cancer Journal|October 12, 2018
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestryLinda B Baughn, Kathryn Pearce, Dirk Larson, et al.
Blood Cancer Journal|April 12, 2022
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantationAbdullah S Al Saleh, Mohammad S Ebraheem, M Hasib Sidiqi, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood Cancer Journal|November 17, 2018
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myelomaPraful Ravi, Shaji K Kumar, Lindsey Roeker, et al.
Mayo Clinic Proceedings|May 6, 2015
Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin depositsGauri Bhutani, Samih H Nasr, Samar M Said, et al.
American Journal of Clinical Pathology|May 19, 2023
Proteomic and Clinicopathologic Assessment of Penile Amyloidosis: A Single Institutional Review of 12 CasesBurak Tekin, Sarwat I Gilani, Surendra Dasari, et al.
Cancer|June 29, 2019
Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysisRonan W Hsieh, Ronald S Go, Jithma P Abeykoon, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
Hemasphere|December 31, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab eraAbdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hegenbart, et al.
Pageof 76

Showing results (481-490 of 759) with videos related to

Sort By:
Pageof 76
Blood Cancer Journal|October 12, 2018
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestryLinda B Baughn, Kathryn Pearce, Dirk Larson, et al.
Blood Cancer Journal|April 12, 2022
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantationAbdullah S Al Saleh, Mohammad S Ebraheem, M Hasib Sidiqi, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood Cancer Journal|November 17, 2018
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myelomaPraful Ravi, Shaji K Kumar, Lindsey Roeker, et al.
Mayo Clinic Proceedings|May 6, 2015
Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin depositsGauri Bhutani, Samih H Nasr, Samar M Said, et al.
American Journal of Clinical Pathology|May 19, 2023
Proteomic and Clinicopathologic Assessment of Penile Amyloidosis: A Single Institutional Review of 12 CasesBurak Tekin, Sarwat I Gilani, Surendra Dasari, et al.
Cancer|June 29, 2019
Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysisRonan W Hsieh, Ronald S Go, Jithma P Abeykoon, et al.
American Journal of Hematology|March 11, 2015
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin TAngela Dispenzieri, Morie A Gertz, Amy Saenger, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
Hemasphere|December 31, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab eraAbdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hegenbart, et al.
Pageof 76